Selection and prioritization of candidate combination regimens for the treatment of tuberculosis [PDF]
Accelerated tuberculosis drug discovery has increased the number of plausible multidrug regimens. Testing every drug combination in vivo is impractical, and varied experimental conditions make it challenging to compare results between experiments.
Chaba, Linda +7 more
core +1 more source
Candidate anti-tuberculosis medicines and regimens under clinical evaluation [PDF]
Background: Tuberculosis (TB) is the leading cause of mortality by an infectious disease worldwide. Despite national and international efforts, the world is not on track to end TB by 2030.
Barros-Aguirre, David +7 more
core +1 more source
AN OVERVIEW ON TUBULARCULOSIS TREATMENT IN CURRENT SCENARIO [PDF]
, 2020 The causative agent of tuberculosis (TB) is Mycobacterium tuberculosis, which mainly infects lungs and causes severe, fever, weight loss, chest pain, etc. It is an extremely transmittable disease spreaded throughout the world as per the WHO.
BUDHORI, AMIT +3 more
core +1 more source
The Tuberculosis Treatment Pipeline: Activity, but No Answers [PDF]
, 2016 In the past year, the development of new tuberculosis (TB) drug candidates experienced some setbacks as well as some wise pruning, with the unexpected suspension of enrollment in STAND (a phase III combination trial that includes the new drug pretomanid),
Erica Lessem
core
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies [PDF]
, 2018 Tuberculosis remains the world's leading cause of death from an infectious disease, responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of rifampicin-resistant tuberculosis in 2016-of which 490 000 were multidrug resistant
du Plessis, N +13 more
core +1 more source
In Vitro Efficacy Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Rapid Growing Mycobacteria Isolated in Beijing, China [PDF]
, 2021 Shu’an Wen +9 more
openalex +1 more source
Hubungan Kadar Kalium dan Kadar Ureum Terhadap Jenis Obat Baru pada Pasien Tuberkulosis Resistan Obat (TB RO) [PDF]
The use of new types of drugs in RO TB patients will cause disturbances in the body's electrolytes, especially potassium levels, as well as disturbances in urea levels caused by the excretion of urea that is retained in the body.
Anggita, Sasha Marwah +2 more
core +1 more source
Бедаквилин в лечении лекарственно-устойчивого туберкулеза [PDF]
, 2021 Bedaquiline in the treatment of resistant tuberculosis.Scopul studiului s-a redus la elucidarea şi analiza asocierilor bedaquilinei (Bdq) cu preparatele antituberculoase de linia a II-a în tratamentul tuberculozei multudrodrezestentă şi cu ...
Bacinschi, Nicolae +6 more
core +1 more source
Development and application of the direct mycobacterial growth inhibition assay: a systematic review [PDF]
Introduction: First described by Wallis et al. in 2001 for the assessment of TB drugs, the direct mycobacterial growth inhibition assay (MGIA) offers a tractable ex vivo tool measuring the combined influences of host immunity, strain virulence and ...
Fletcher, Helen +4 more
core +2 more sources
Accelerating the development of therapeutic strategies for drug-resistant tuberculosis [PDF]
, 2018 Recent progress in the discovery, development and evaluation of new drugs and combination regimens for drug-resistant tuberculosis through greater collaboration between industry, donors and academia provides renewed hope for overcoming the challenges in ...
Tiberi, S, Vjecha, MJ, Zumla, A
core +1 more source